This might explain the success of T-DXd in Her-2 low advanced breast cancer [48] and the higher sensitiveness to T-DXd observed in tumors harboring heterogeneous Her-2 expression, such as colorectal and non-small-cell lung cancer, in comparison with other anti-Her-2 agents [49]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.